We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

66 hedge funds and large institutions have $117M invested in ChemoCentryx, Inc. in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

2% more funds holding

Funds holding: 6566 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

57% less capital invested

Capital invested by funds: $273M → $117M (-$156M)

72% less call options, than puts

Call options by funds: $419K | Put options by funds: $1.51M

Holders
66
Holders Change
+1
Holders Change %
+1.54%
% of All Funds
2.14%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
30
Reduced
14
Closed
15
Calls
$419K
Puts
$1.51M
Net Calls
-$1.09M
Net Calls Change
-$1.09M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$29.9M +$3.79M +350,850 +7%
Capital World Investors
2
Capital World Investors
California
$17.4M +$11.5M +1,060,217 +51%
RCM
3
RA Capital Management
Massachusetts
$16.9M +$32.9M +3,045,380 New
WA
4
Wasatch Advisors
Utah
$9.71M +$1.09M +100,890 +6%
Franklin Resources
5
Franklin Resources
California
$4.82M +$1.9M +176,000 +25%
BFA
6
BlackRock Fund Advisors
California
$3.88M +$920K +85,053 +14%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$3.6M -$261K -24,100 -4%
Balyasny Asset Management
8
Balyasny Asset Management
Illinois
$2.68M +$5.22M +482,400 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$2.65M +$71.8K +6,643 +1%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$1.95M +$1.08M +100,000 +40%
State Street
11
State Street
Massachusetts
$1.84M +$189K +17,445 +6%
Northern Trust
12
Northern Trust
Illinois
$1.81M +$1.72M +158,680 +95%
GGHC
13
Gilder Gagnon Howe & Co
New York
$1.81M -$9.5M -878,703 -73%
BIM
14
Bogle Investment Management
Massachusetts
$1.78M +$3.46M +319,868 New
BIT
15
BlackRock Institutional Trust
California
$1.6M +$8.48K +784 +0.3%
AG
16
Artal Group
Luxembourg
$1.53M
JP Morgan Chase
17
JP Morgan Chase
New York
$1.28M -$2.51M -231,878 -50%
BBA
18
Baker Bros. Advisors
New York
$1.11M -$1.89M -175,000 -47%
PI
19
Putnam Investments
Massachusetts
$1.11M
Millennium Management
20
Millennium Management
New York
$930K -$1.3M -120,418 -42%
CS
21
Credit Suisse
Switzerland
$909K +$1.51M +139,675 +585%
Morgan Stanley
22
Morgan Stanley
New York
$816K +$1.35M +124,934 +575%
NI
23
Numeric Investors
Massachusetts
$761K -$407K -37,655 -22%
TCIM
24
TIAA CREF Investment Management
New York
$727K +$99.1K +9,162 +8%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$543K +$31.3K +2,890 +3%

CCXI Hedge Fund Activity: Q3 2013 in Review

66 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q3 2013, worth a combined $117M — down 57% from $273M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new CCXI positions and 15 closed out — a net gain of 1 holder — while 30 added to existing stakes and 14 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $32.9M. The largest seller was Jennison Associates, exiting entirely with an estimated $30.4M sold.

  • 66 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q3 2013, up from 65 in Q2 2013.
  • Funds reported $117M of ChemoCentryx, Inc. stock for Q3 2013, down 57% quarter-over-quarter.
  • 16 funds opened new ChemoCentryx, Inc. positions in Q3 2013 and 15 closed out, a net change of +1 holder.
  • The largest ChemoCentryx, Inc. buyer in Q3 2013 was RA Capital Management, an estimated $32.9M added.
  • The largest ChemoCentryx, Inc. seller in Q3 2013 was Jennison Associates, an estimated $30.4M sold.

Based on aggregated 13F filings for Q3 2013.